Citations

Showing 10 of 108094 citations.

P-034 Common data elements reported on middle meningeal artery embolization in chronic subdural hematoma: an interactive systematic review of recent trials
Adusumilli, G, Ghozy, Sherief , Kallmes, K, Hardy, Nick, Tarchand, R, Zinn, C, Lamar, D, Singeltary, E, Siegel, L, Kallmes, D, Arthur, A, Gellißen, S, Fiehler, J, Heit, Jeremy J , Ghozy, Sherief , Kallmes, Kevin M , Tarchand, Ranita , Zinn, Caleb, Lamar, Duncan, Singeltary, Emily, Kallmes, David F. , Fiehler, Jans, Heit, Jeremy J

Mayo Clinic

SNIS 19th annual meeting oral poster abstracts | July 23, 2022 | Volume: No volume available | Issue: No issue available | Pages: A70.2-A71

10.1136/neurintsurg-2022-snis.106 Get It

Early readmissions of spontaneous bacterial peritonitis in the USA: Insights into an emerging challenge
Dahiya, Dushyant Singh , Sanaka, Madhusudhan R. , Kichloo, Asim , Singh, Amandeep , Wachala, Jennifer, Perisetti, Abhilash , Goyal, Hemant , Garg, Rajat , Shaka, Hafeez , Pisipati, Sailaja , Inamdar, Sumant , Al-Haddad, Mohammad , Dahiya, Dushyant Singh , Al‐Haddad, Mohammad

Mayo Clinic

Journal of Gastroenterology and Hepatology | July 23, 2022 | Volume: 37 | Issue: 11 | Pages: 2067-2073

10.1111/jgh.15965 | PMID 35869617 Get It

AbstractBackground and AimEarly readmissions of spontaneous bacterial peritonitis (SBP) are often associated with poor outcomes. We compared characteristics and outcomes for index and 30‐day readmissions of SBP in the USA.MethodsWe analyzed the Nationwide Readmissions Database for 2018 to identify all adult (≥ 18 years) 30‐day readmissions of SBP in the USA. Hospitalization characteristics and outcomes for index and 30‐day readmissions of SBP were compared. Independent predictors of 30‐day readmissions were also identified.ResultsIn 2018, of the 5,797 index admissions for SBP, 30% (1726) were readmitted within 30 day. At the time of readmission, the most common admitting diagnosis was alcoholic cirrhosis of the liver with ascites (11.8%) followed by sepsis due to an unspecified organism (9.2%). SBP as an admitting diagnosis was identified for only 8.3% of these 30‐day readmissions. Compared with index admissions, 30‐day readmissions of SBP had a lower mean age (56.1 vs 58.6 years, P < 0.001) without a statistically significant difference for gender. Furthermore, 30‐day readmissions of SBP were associated with significantly higher odds of inpatient mortality (10% vs 4.9%, OR: 2.15, 95% CI: 1.66–2.79, P < 0.001), and mean total hospital charge ($85,031 vs $56,000, mean difference: 29,032, 95% CI: 12,867–45,197, P < 0.001) compared with index admissions. The presence of chronic pulmonary disease, liver failure, inpatient dialysis, and discharge against medical advice were identified as independent predictors for increased 30‐day readmissions of SBP.ConclusionThe 30‐day readmission rate of SBP was 30% and these readmissions were associated with higher odds of inpatient mortality compared with index admissions.
Development of a Prediction Model for COVID‐19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry
Izadi, Zara , Aguirre, Alfredo , Hyrich, Kimme L , Gossec, Laure , Carmona, Loreto , Lawson‐Tovey, Saskia , Kearsley‐Fleet, Lianne , Schaefer, Martin, Seet, Andrea M. , Schmajuk, Gabriela , Jacobsohn, Lindsay, Rush, Stephanie, Sparks, Jeffrey A. , Hsu, Tiffany , Gilbert, Emily, Valenzuela-Almada, Maria O , Ugarte‐Gil, Manuel F. , Ribeiro, Sandra Lúcia Euzébio , Marinho, Adriana de Oliveira , Valadares, Lílian David de Azevedo , Hasseli, Rebecca , Richter, Jutta , Schmeiser, Tim , Torres, Alvaro Andres Reyes , Alle, Gelsomina , Saurit, Verónica , Zanetti, Anna , Carrara, Greta , Labreuche, Julien , Barnetche, Thomas , Hérasse, Muriel, Plassart, Samira, Santos, María José , Machado, Pedro , Sirotich, Emily , Hausmann, Jonathan S. , Sufka, Paul , Grainger, Rebecca , Bhana, Suleman , Costello, Wendy, Wallace, Zachary S. , Registry, Global Rheumatology Alliance, Schäfer, Martin , Gianfrancesco, Milena A , Aguirre, Alfredo , Lawson-Tovey, Saskia , Kearsley-Fleet, Lianne , Schaefer, Martin , Schmajuk, Gabriela , Katz, Patricia , Al-Emadi, Samar , Sparks, Jeffrey A , Wise, Leanna M , Duarte-García, Alí , Ribeiro, Sandra Lúcia Euzébio , Pfeil, Alexander , Santos, Maria José , Robinson, Philip C , Machado, Pedro M , Hausmann, Jonathan S , Grainger, Rebecca , Yazdany, Jinoos , Ugarte-Gil, Manuel F , Carmona, Loreto , Gossec, Laure , Hasseli, Rebecca , Hyrich, Kimme L , Sirotich, Emily , Hsu, Tiffany Y-T , Mateus, Elsa F , Strangfeld, Anja , Mateus, Elsa F , Katz, Patricia , Patel, Naomi J , Wise, Leanna , Duarte‐García, Alí , Di Giuseppe, Daniela , Isnardi, Carolina A , Saurit, Verónica , Khaldi-Plassart, Samira , Rodrigues, Ana Maria , Robinson, Philip C. , Liew, Jean W. , Yazdany, Jinoos , Registry, Global Rheumatology Alliance

Mayo Clinic

ACR Open Rheumatology | July 23, 2022 | Volume: 4 | Issue: 10 | Pages: 872-882

10.1002/acr2.11481 | PMID 35869686 Get It

ObjectiveSome patients with rheumatic diseases might be at higher risk for coronavirus disease 2019 (COVID‐19) acute respiratory distress syndrome (ARDS). We aimed to develop a prediction model for COVID‐19 ARDS in this population and to create a simple risk score calculator for use in clinical settings.MethodsData were derived from the COVID‐19 Global Rheumatology Alliance Registry from March 24, 2020, to May 12, 2021. Seven machine learning classifiers were trained on ARDS outcomes using 83 variables obtained at COVID‐19 diagnosis. Predictive performance was assessed in a US test set and was validated in patients from four countries with independent registries using area under the curve (AUC), accuracy, sensitivity, and specificity. A simple risk score calculator was developed using a regression model incorporating the most influential predictors from the best performing classifier.ResultsThe study included 8633 patients from 74 countries, of whom 523 (6%) had ARDS. Gradient boosting had the highest mean AUC (0.78; 95% confidence interval [CI]: 0.67‐0.88) and was considered the top performing classifier. Ten predictors were identified as key risk factors and were included in a regression model. The regression model that predicted ARDS with 71% (95% CI: 61%‐83%) sensitivity in the test set, and with sensitivities ranging from 61% to 80% in countries with independent registries, was used to develop the risk score calculator.ConclusionWe were able to predict ARDS with good sensitivity using information readily available at COVID‐19 diagnosis. The proposed risk score calculator has the potential to guide risk stratification for treatments, such as monoclonal antibodies, that have potential to reduce COVID‐19 disease progression.
Extramedullary Acute Myeloid Leukemia in the De Novo Setting: Clinicopathologic Characteristics, Molecular Analysis, and Treatment Outcomes
Kuhlman, Justin J. , McCormick, Benjamin J. , Jiang, Liuyan , Menke, David M. , Badar, Talha , Kharfan‐Dabaja, Mohamed A. , Foran, James M. , Rahman, Zaid Abdel , Rahman, Zaid H. Abdel , Abdel Rahman, Zaid H , Badar, Talha , Kuhlman, Justin , Murthy, Hemant S.

Mayo Clinic

No container title available | July 22, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1832465/v1 Get It

Abstract Extramedullary disease in acute myeloid leukemia (AML), also known as myeloid sarcoma (MS), is an uncommon presentation of de novo AML. We analyzed medical records of patients in the Mayo Clinic database spanning between 1996 and 2021 who were diagnosed with de novo extramedullary AML. Survival outcomes were analyzed using Kaplan-Meier and Cox-proportional hazard models for univariate and multivariate analysis, respectively. With a median follow-up of 20.7 months, 83 patients with de novo MS were identified; 49 presented with synchronous MS and 34 with isolated MS. Next generation sequencing (NGS) revealed RTK-RAS pathway mutations in 44% of patients. Median overall survival (OS) was 25.3 months and 17.8 months in isolated and synchronous MS, respectively (p = 0.49). Variables associated with improved OS on univariate analysis included treatment with intensive chemotherapy (p < 0.001), normal or favorable risk karyotype (p = 0.001), age less than 60 years (p = 0.001), and a complete response to treatment at extramedullary sites (p < 0.0001). On multivariate analysis, normal or favorable risk karyotype (p = 0.001), age less than 60 (p = 0.01), and a complete extramedullary response (p = 0.001) were associated with improved OS. Localized therapy did not provide added survival benefit in isolated MS. Genomic stratification, age, and extramedullary site response are predictive of survival outcomes.
Phase II Study of Enzalutamide for Patients With Androgen Receptor–Positive Salivary Gland Cancers (Alliance A091404)
Ho, Alan L. , Foster, Nathan R. , Zoroufy, Alexander , Campbell, Jordan D., Price, Katharine A., Adkins, Douglas R. , Bowles, Daniel W. , Kang, Hyunseok , Sherman, Eric J. , Morton, Roscoe F., Nadeem, Zaineb , Katabi, Nora , Münster, Pamela N. , Price, Katharine, Adkins, Douglas , Bowles, Daniel W , Kang, Hyunseok , Burtness, Barbara , Sherman, Eric , Morris, Luc G T , Munster, Pamela , Ho, Alan L , Worden, Francis P. , Burtness, Barbara , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | July 22, 2022 | Volume: 40 | Issue: 36 | Pages: 4240-4249

10.1200/jco.22.00229 | PMID 35867947 Get It

PURPOSE The androgen receptor (AR) is expressed (+) in a subset of salivary gland cancers (SGCs). This phase II trial evaluated the efficacy of the antiandrogen enzalutamide in AR+ SGC. METHODS Patients with locally advanced/unresectable or metastatic AR+ SGCs were enrolled. Enzalutamide (160 mg) was given orally once daily. The primary end point was the best overall response rate per RECIST v1.1 within eight cycles. Confirmed responses in ≥ 5 of 41 patients would be considered promising. Secondary end points were progression-free survival, overall survival, and safety. RESULTS Forty-six patients were enrolled; 30 (65.2%) received prior systemic therapy, including 13 (28.3%) with AR-targeted drugs. Of seven (15.2%) partial responses (PRs), only two (4.3%) were confirmed per protocol and counted toward the primary end point. Twenty-four patients (52.2%) had stable disease; 15 (32.6%) had progression of disease as best response. Twenty-six patients (56.5%) experienced tumor regression in target lesions; 18 (39.1%) had partial response/stable disease ≥ 6 months. Tumor regressions were observed in female patients (5 of 6 [83.3%]) and those who received prior AR– (6 of 13 [46.2%]) or human epidermal growth factor receptor 2–targeted therapies (5 of 8 [62.5%]). Three patients remained on treatment at data cutoff (duration, 32.2-49.8 months). The median progression-free survival was 5.6 months (95% CI, 3.7 to 7.5); the median overall survival was 17.0 months (95% CI, 11.8 to 30.0). The most common adverse events were fatigue, hypertension, hot flashes, and weight loss. Total and free testosterone levels increased by a mean of 61.2% and 48.8%, respectively, after enzalutamide. CONCLUSION Enzalutamide demonstrated limited activity in AR+ SGC, failing to meet protocol-defined success in part because of a lack of response durability. Strategies to enhance the efficacy of antiandrogen therapy are needed.
Concussions in the Women’s National Basketball Association: Analysis of Incidence, Return-to-Play Timing, and Player Performance From 1997 to 2020
Walker, Jasmine J. , Dancy, Malik, Okoroha, Kelechi R. , Kharrazi, F. Daniel, Mehran, Nima , Marigi, Erick M.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | July 22, 2022 | Volume: 10 | Issue: 7 | Pages: No page available

10.1177/23259671221105257 | PMID 35898206 Get It

Background: The extent to which concussions affect Women’s National Basketball Association (WNBA) athletes has not been thoroughly examined. Purpose: To evaluate the incidence and impact of concussion injuries occurring in the WNBA. Study Design: Descriptive epidemiology study. Methods: Publicly available records were searched to identify all documented basketball-related concussions from WNBA seasons 1997 to 2020. Player demographics, injury details, and basketball career information were collected. Concussion incidence and return-to-play (RTP) timing were evaluated before and after the institution of the WNBA concussion protocol in 2012. Minutes per game and game score per minute were compared 5 games before and 5 games after the concussion was sustained. Player game availability and RTP performance were also compared with an age-, body mass index–, position-, and experience-matched control group of players who did not sustain any injuries during the index season. Results: A total of 70 concussions among 55 players were reported in the WNBA from 1997 to 2020, with a mean incidence of 2.9 ± 2.3 concussions per season. After the implementation of the WNBA concussion protocol, the incidence significantly increased from 1.7 to 5.0 concussions per season ( P < .001). All players returned after a first-time concussion, missing a mean of 3.8 ± 4.7 games and 17.9 ± 20.7 days. After the adoption of the concussion protocol, the time to RTP significantly increased with games missed ( P = .006) and days missed ( P = .006). Minutes per game and game score per minute were not significantly affected by sustaining a concussion ( P = .451 and P = .826, respectively). Conclusion: Since the adoption of the WNBA concussion protocol in the 2012 season, the incidence of concussions increased significantly. Athletes retained a high rate of RTP after missing a median of 4 games, and the time to RTP increased after the institution of the concussion protocol. Player game availability and performance within the same season were not significantly affected by concussion injuries after a successful RTP.
Risk factors of posttraumatic empyema in diaphragmatic injuries 
Rodríguez, Fernando , Gallego, Carlos, Naranjo, María Paula , Currea-Perdomo, Diana Felisa, Ordóñez, Carlos A. , Puyana, Juan Carlos , Ordoñez, Carlos A , Garcı́a, Alberto , Sánchez, Á. , Caicedo-Holguín, Isabella , Gallego, Carlos, Caicedo, Yaset , Burbano, Daniela

Mayo Clinic

No container title available | July 22, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1862785/v1 Get It

Abstract Background: Penetrating diaphragmatic injuries are associated with a high incidence of posttraumatic empyema. We analyzed the contribution of trauma severity, specific organ injury, contamination severity, and surgical management to the risk of Posttraumatic empyema in patients who underwent surgical repair of diaphragmatic injuries at a level 1 trauma center.Methods: This is a retrospective review of the patients who survived more than 48 hours. Univariate OR calculations were performed to identify potential risk factors. Multiple logistic regression was used to calculate adjusted ORs and identify independent risk factors.Results: We included 192 patients treated from 2011 to 2020. There were 169 (88.0) male. The mean interquartile range, (IQR) of age was 27 (22 - 35) years. Gunshot injuries occurred in 155 subjects (80.7%). Mean (IQR) NISS and ATI were 29 (18 - 44) and 17 (10 - 27), respectively. Thoracic AIS was >3 in 38 patients (19.8%). Hollow viscus was injured in 105 cases (54.7%). Stomach in 65 (33.9%), colon in 52 (27.1%), small bowel in 42 (21.9%), and duodenum in 10 (5.2%). Visible contamination was found in 76 patients (39.6%).Potential thoracic contamination was managed with a chest tube in 128 cases (66.7%), with transdiaphragmatic pleural lavage in 42 (21.9%), and with Video Assisted Thoracoscopy Surgery or thoracotomy in 22 (11.5%). Empyema occurred in 11 patients (5.7%). Multiple Logistic Regression identified thoracic AIS >3 (OR 6.4, 95% CI 1.77 – 23. 43), and visible contamination (OR 5.13, 95% IC 1.26 – 20.90) as independent risk factors. The individual organ injured, or the method used to manage the thoracic contamination did not affect the risk of posttraumatic empyema.Conclusion: The severity of the thoracic injury and the presence of visible abdominal contamination were identified as independent risk factors of empyema after penetrating diaphragmatic trauma.
High prevalence of gram-negative and multiorganism surgical site infections after pediatric complex tethered spinal cord surgery: a multicenter study
Alexiades, Nikita G. , Shao, Belinda , Ahn, Edward S. , Blount, Jeffrey P. , Brockmeyer, Douglas L. , Hankinson, Todd C. , Sandberg, David I. , Heuer, Gregory G. , Feldstein, Neil A. , Anderson, Richard C. E. , Nesvick, Cody L. , Saiman, Lisa M.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | July 22, 2022 | Volume: 30 | Issue: 3 | Pages: 357-363

10.3171/2022.6.peds2238 | PMID 35901675 Get It

OBJECTIVE Complex tethered spinal cord (cTSC) release in children is often complicated by surgical site infection (SSI). Children undergoing this surgery share many similarities with patients undergoing correction for neuromuscular scoliosis, where high rates of gram-negative and polymicrobial infections have been reported. Similar organisms isolated from SSIs after cTSC release were recently demonstrated in a single-center pilot study. The purpose of this investigation was to determine if these findings are reproducible across a larger, multicenter study. METHODS A multicenter, retrospective chart review including 7 centers was conducted to identify all cases of SSI following cTSC release during a 10-year study period from 2007 to 2017. Demographic information along with specific microbial culture data and antibiotic sensitivities for each cultured organism were collected. RESULTS A total of 44 SSIs were identified from a total of 655 cases, with 78 individual organisms isolated. There was an overall SSI rate of 6.7%, with 43% polymicrobial and 66% containing at least one gram-negative organism. Half of SSIs included an organism that was resistant to cefazolin, whereas only 32% of SSIs were completely susceptible to cefazolin. CONCLUSIONS In this study, gram-negative and polymicrobial infections were responsible for the majority of SSIs following cTSC surgery, with approximately half resistant to cefazolin. Broader gram-negative antibiotic prophylaxis should be considered for this patient population.
Intrasaccular flow disruption for ruptured aneurysms: an international multicenter study
Diestro, Jose Danilo Bengzon , Dibas, Mahmoud , Adeeb, Nimer , Regenhardt, Robert W. , Vranic, Justin E. , Guenego, Adrien , Lay, Sovann V. , Balushi, Ali Al , Shotar, Eimad , Premat, Kévin , Möhlenbruch, Markus , Foreman, Paul M. , Vachhani, Jay A. , Župančić, Vedran , Hafeez, Muhammad Ubaid , Rai, Hamid, Tutino, Vincent M. , Mirshani, Shervin, Ghozy, Sherief , Alotaibi, Naif M. , Rabinov, James D. , Ren, Yifan , Goren, Oded , Piano, Mariangela , Michelozzi, Caterina , Elens, Stéphanie , Starke, Robert M. , Nguyên, Anh , Jones, Jesse , Psychogios, Marios, Spears, Julian , Bullrich, María Bres , Mayich, Michael , Salem, Mohamed M. , Burkhardt, Jan‐Karl , Jankowitz, Brian T. , Ulfert, Christian , Lubicz, Boris , Puri, Ajit S , Pero, Guglielmo , Asadi, Hamed , Siddiqui, Adnan H. , Ducruet, Andrew F. , Albuquerque, Felipe C , Kan, Peter , Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Stapleton, Christopher J. , Knopman, Jared , Jabbour, Pascal , Tjoumakaris, Stavropoula , Clarençon, Frédéric , Aziz‐Sultan, Mohammad Ali , Patel, Aman B. , Dmytriw, Adam A. , Shotar, Eimad , Saliou, Guillaume , Lylyk, Ivan , Vachhani, Jay A , Rai, Hamid , Tutino, Vincent M , Harker, Pablo , Ren, Yifan , Schirmer, Clemens M , Michelozzi, Caterina , Elens, Stephanie , Hassan, Ameer E , Nguyen, Anh , Jones, Jesse , Parra-Fariñas, Carmen , Salem, Mohamed M , Domingo, Ricardo A , Tawk, Rabih, Pero, Guglielmo , Albuquerque, Felipe C , Kan, Peter , Kalousek, Vladimir , Jabbour, Pascal , Tjoumakaris, Stavropoula , Clarençon, Frédéric , Cuellar-Saenz, Hugo H , Dmytriw, Adam A , Siddiqui, Adnan H , Dibas, Mahmoud , Ghozy, Sherief , Diestro, Jose Danilo B , Regenhardt, Robert W , Hafeez, Muhammad U , Ulfert, Christian , Lay, Sovann V , Burkhardt, Jan‐Karl , Renieri, Leonardo , Naamani, Kareem El , Saliou, Guillaume , Lylyk, Iván , Rutledge, Caleb , Harker, Pablo , Schirmer, Clemens M. , Kühn, Anna Luisa , Hassan, Ameer E , Salehani, Arsalaan , Psychogios, Marios‐Nikos , Domingo, Ricardo A. , Huynh, Thien , Tawk, Rabih G. , Panni, Pietro , Griessenauer, Christoph J. , Du, Rose , Jabbour, Pascal , Limbucci, Nicola , Cuellar, Hugo , Cognard, Christophe

Mayo Clinic

Journal of NeuroInterventional Surgery | July 22, 2022 | Volume: 15 | Issue: 9 | Pages: 844-850

10.1136/jnis-2022-019153 | PMID 35868856 Get It

Background The Woven EndoBridge (WEB) device is a novel intrasaccular flow disruptor tailored for bifurcation aneurysms. We aim to describe the degree of aneurysm occlusion at the latest follow-up, and the rate of complications of aneurysms treated with the WEB device stratified according to rupture status. Methods Our data were taken from the WorldWideWeb Consortium, an international multicenter cohort including patients treated with the WEB device. Aneurysms were classified into two groups: ruptured and unruptured. We compared clinical and radiologic outcomes of both groups. Propensity score matching (PSM) was done to match according to age, gender, bifurcation, location, prior treatment, neck, height, dome width, daughter sac, incorporated branch, pretreatment antiplatelets, and last imaging follow-up. Results The study included 676 patients with 691 intracranial aneurysms (529 unruptured and 162 ruptured) treated with the WEB device. The PSM analysis had 55 pairs. In both the unmatched (85.8% vs 84.3%, p=0.692) and matched (94.4% vs 83.3%, p=0.066) cohorts there was no significant difference in the adequate occlusion rate at the last follow-up. Likewise, there were no significant differences in both ischemic and hemorrhagic complications between the two groups. There was no documented aneurysm rebleeding after WEB device implantation. Conclusion There was no significant difference in both the radiologic outcomes and complications between unruptured and ruptured aneurysms. Our findings support the feasibility of treatment of ruptured aneurysms with the WEB device.